MEDIA & PRESS UPDATES

July 22, 2019

Novel, Non-Invasive Drug Delivery Platform Expands Glaukos’ Portfolio of Sustained Pharmaceutical Systems

Includes Lead Candidate for Treatment of Dry Eye Disease with Potential Future Candidates for Other Corneal Disorders and Glaucoma

​

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions.

Intratus’ patented cream-based drug formulations are applied to the outer surface of the eyelid for transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. Early human studies with this novel delivery system have demonstrated efficacy without the side effects often associated with drugs delivered as topical eye drops.

“This licensing agreement adds a novel drug delivery platform using a differentiated, non-invasive transdermal approach to our expanding portfolio of sustained pharmaceutical systems,” said Thomas Burns, Glaukos president and chief executive officer. “Intratus’ proprietary transdermal drug delivery application is highly complementary to our expanding portfolio of sustained pharmaceutical systems and represents a synergistic fit with our glaucoma and corneal health R&D initiatives. With this agreement, we plan to build upon the promising development work Intratus has completed to advance this exciting new drug delivery approach into the appropriate clinical phases.”

“Intratus’ drug delivery platforms aim to provide an efficacious, safe and durable treatment option for ophthalmic diseases through a simple, non-invasive and patient-friendly method of application,” said Aaron Dyer, co-founder and chief executive officer, and Padma Nanduri, M.D. FACS, co-founder and chief medical officer. “We believe Glaukos’ proven track record in pioneering new treatment paradigms makes them the perfect partner to help bring our novel treatment options, if approved, to patients and physicians in the most effective and timely manner possible.”

Under the agreement, Glaukos will obtain an exclusive global license to Intratus’ drug delivery technology for use in the treatment of glaucoma and corneal disorders, including dry eye disease, allergy, blepharitis, conjunctivitis and related conditions. Financial terms of the agreement were not disclosed.

​

About Intratus, Inc.

Intratus, Inc. is a privately held life sciences company dedicated to utilizing its patented novel drug delivery platform technologies for the treatment of ophthalmic diseases and disorders. Intratus is headquartered in San Diego, California.

​

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject® device in the United States in September 2018. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease